Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640443 | 0.86 | GPR84 (0.39) | GPR84ALDH1A1LMNAMTNR1AMTNR1B | |
| SCHEMBL3251019 | 0.81 | NOTUM (0.59) | GPR84MTNR1AMTNR1BNOTUMMPO | |
| SCHEMBL4641323 | 0.73 | TNF (0.65) | GPR84TNFTACR1 | |
| SCHEMBL14487642 | 0.73 | GPR84 (0.65) | GPR84ALDH1A1LMNATNFMPO | |
| SCHEMBL5791055 | 0.72 | GPR84 (0.59) | GPR84ALDH1A1LMNAMTNR1AMTNR1B | |
| SCHEMBL13954293 | 0.72 | GPR84 (0.73) | GPR84ALDH1A1LMNAMPOHTR1A | |
| SCHEMBL14487390 | 0.71 | GPR84 (0.58) | GPR84ALDH1A1LMNAMTNR1AMTNR1B | |
| SCHEMBL4641342 | 0.68 | GPR84 (0.47) | GPR84ALDH1A1LMNAMPOHTR1A | |
| SCHEMBL29751089 | 0.68 | TNF (0.61) | GPR84ALDH1A1LMNATNFMPO | |
| SCHEMBL6844425 | 0.68 | TNF (0.61) | GPR84ALDH1A1LMNATNFMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | GPR84 304/4885ALDH1A1 3513/4885LMNA 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.